Tax policy changes affecting cannabis companies directly impact patient access and medication costs. When companies face lower tax burdens, they can potentially reduce product prices and invest more in quality control and research, affecting the therapeutic options available to patients.
The Department of Justice is considering policy changes that could reduce the tax burden on cannabis companies, potentially through modifications to Section 280E enforcement or related tax provisions. Current federal tax law prevents cannabis businesses from deducting standard business expenses, creating significant financial pressures that are often passed to consumers. Lower operational costs could translate to improved product accessibility and affordability for medical cannabis patients.
“I see this as potentially meaningful for patient access — high cannabis costs are a real barrier in my practice. However, I’m watching for whether any savings actually reach patients rather than just improving company margins.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
